Drug Trial Radar · NCT06663436
A Study on the Immune Response and Safety of a Multicomponent Shigella Vaccine in Preventing Shigellosis in Infants
Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
200
Actual
Start
Nov 13, 2024
Primary completion
Oct 21, 2025
Study completion Oct 21, 2025
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Oct 29, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 39 weeks, up to 43 weeks
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study evaluates the immune response and safety of a multicomponent, 2-dose Shigella vaccine in preventing shigellosis in African infants. The candidate vaccine, altSonflex1-2-3, is currently being evaluated in a Phase 2 age de-escalation (from least vulnerable adult population to most vulnerable paediatric population) clinical study in Kenya, with the aim of identifying a preferred dose, using a 3-dose vaccination schedule in infants from 9 months of age (NCT05073003). This Phase 2 clinical study will evaluate the safety and immunogenicity of an alternative 2-dose vaccination schedule.
Conditions
- Diarrhoea
Interventions
altSonflex1-2-3 Dose ABiological
altSonflex1-2-3 Dose A administered intramuscularly on Day 1 and Day 169
altSonflex1-2-3 Dose BBiological
altSonflex1-2-3 Dose B administered intramuscularly on Day 1 and Day 169
altSonflex1-2-3 Dose CBiological
altSonflex1-2-3 Dose C administered intramuscularly on Day 1 and Day 169
TYPHIBEVBiological
TYPHIBEV administered intramuscularly on Day 1
Infanrix hexaCombination product
Infanrix hexa administered intramuscularly on Day 169
MR-VACBiological
MR-VAC co-administered subcutaneously on Day 1 and Day 169
Primary outcomes
What the sponsor says the trial is designed to measure.
- Geometric Mean Concentrations (GMCs) of Anti-serotype Specific Shigella Lipopolysaccharide (LPS)/O-Antigen (OAg) Serum Immunoglobulin G (IgG)Time frame: At Day 1 (before administration of Dose 1)
- GMCs of Anti-serotype Specific Shigella LPS/OAg Serum IgGTime frame: At Day 29 (28 days after administration of Dose 1)
- GMCs of Anti-serotype Specific Shigella LPS/OAg Serum IgGTime frame: At Day 169 (before administration of Dose 2)
- GMCs of Anti-serotype Specific Shigella LPS/OAg Serum IgGTime frame: At Day 197 (28 days after administration of Dose 2)
- Number of Participants With at Least a 4-fold Increase in Anti-serotype Specific Shigella LPS/OAg Serum IgGTime frame: At Day 29 compared to baseline (before administration of Dose 1 on Day 1)
- Number of Participants With at Least a 4-fold Increase in Anti-serotype Specific Shigella LPS/OAg Serum IgGTime frame: At Day 197 compared to baseline (before administration of Dose 1 on Day 1)
- Number of Participants With at Least a 4-fold Increase in Anti-serotype Specific Shigella LPS/OAg Serum IgGTime frame: At Day 197 compared to pre-Dose 2 at Day 169
Locations
1 site in 1 country. Site status is shown where the registry gives one.
GSK Investigational Site
Kericho, Kenya
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.